AV Graft Market Size, Share, Growth, and Industry Analysis, By Type (ePTFE,Biological Materials,Others), By Application (Hospitals,Clinic), Regional Insights and Forecast to 2035

AV Graft Market Overview

The global AV Graft Market is forecast to expand from USD 357.81 million in 2026 to USD 395.28 million in 2027, and is expected to reach USD 618.5 million by 2035, growing at a CAGR of 10.47% over the forecast period.

The AV Graft Market is expanding due to the rising global prevalence of end-stage renal disease (ESRD), which has surpassed 4.5 million patients requiring dialysis worldwide. Annually, over 3.2 million patients undergo hemodialysis procedures, and nearly 20–25% of these individuals require arteriovenous grafts for long-term vascular access. AV grafts are used when arteriovenous fistulas are not suitable, and product utilization has grown with an increasing aging population. The average patency rate of AV grafts ranges from 12–24 months, driving consistent replacement demand. Materials like expanded polytetrafluoroethylene (ePTFE) dominate with more than 60% usage, while biological materials account for around 25%.

The United States has more than 800,000 patients on dialysis, representing nearly 20% of the global ESRD population. Approximately 70% of these patients rely on hemodialysis, and 15–20% use AV grafts as vascular access solutions. Each year, more than 100,000 new AV graft procedures are performed in the country, with ePTFE grafts accounting for over 65% of usage. The U.S. ESRD incidence is nearly 370 per million population annually, creating consistent demand for vascular access devices. Clinical settings such as hospitals handle more than 75% of AV graft placements, while specialty dialysis clinics conduct the remainder.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 45% of AV graft demand is driven by the rising ESRD prevalence and dialysis dependency worldwide.
• Major Market Restraint: 30% of AV grafts face infection or thrombosis-related complications within 24 months of placement.
• Emerging Trends: 25% of new grafts incorporate heparin bonding or drug-eluting technology for improved patency.
• Regional Leadership: 40% of global AV graft procedures are performed in North America and Europe combined.
• Competitive Landscape: The top 8 players control more than 70% of the global AV graft market share.
• Market Segmentation: ePTFE grafts represent 60% of global usage, biological materials 25%, and others 15%.
• Recent Development: 20% of newly launched grafts in the last three years have focused on infection-resistant coatings.

AV Graft Market Latest Trends

The AV Graft Market is undergoing significant transformation with a focus on enhancing durability and reducing infection risks. Worldwide, over 3.2 million dialysis patients rely on vascular access, and approximately 600,000 patients are living with AV grafts at any given time. One of the notable market trends is the shift toward heparin-bonded ePTFE grafts, which now account for 15–20% of all grafts in use, providing longer patency rates. Biological grafts derived from bovine carotid arteries represent 25% of graft usage and are increasingly used for patients with limited vascular options.

Drug-eluting grafts, although accounting for less than 10% of the current market, have demonstrated reductions in clotting incidents by nearly 30% in recent studies. Another key trend is the adoption of hybrid grafts combining ePTFE and biologics, accounting for 5–7% of procedures, targeting patients with recurrent stenosis. Increasing investments in dialysis centers, especially in Asia-Pacific where more than 1.8 million patients require treatment, are driving new graft placements. Manufacturers are also focusing on graft designs that reduce intervention frequency, with some models reporting up to 40% fewer thrombectomy procedures per patient annually.

AV Graft Market Dynamics

DRIVER

"Rising global prevalence of ESRD and dialysis dependency."

More than 4.5 million people globally live with ESRD, with an incidence rate of 370 per million in the U.S. and 250 per million in Europe. Hemodialysis accounts for 70% of renal replacement therapy, translating into more than 3.2 million dialysis patients. Of these, 20–25% require AV grafts because their vasculature is unsuitable for fistulas. Each year, 100,000–150,000 new AV graft procedures are performed in the U.S., while Europe contributes another 80,000–100,000 placements annually. This rising clinical demand directly supports AV Graft Market Growth.

RESTRAINT

"High infection and thrombosis rates remain major challenges."

AV grafts experience complication rates of 30–40% within 24 months of use, primarily due to infection and stenosis. Infections occur in 10–15% of graft placements, while thrombosis impacts 20–25% of cases. These complications lead to frequent interventions, increasing healthcare costs by up to 20% annually for dialysis patients using grafts. Hospitals report that patients with infected grafts require an average of 1–2 additional procedures per year, compared to those with functioning fistulas. Such clinical risks limit wider adoption and reduce AV Graft Market Opportunities.

OPPORTUNITY

"Advances in biologically enhanced and drug-eluting grafts."

Biological grafts currently make up 25% of the market and have demonstrated superior integration and reduced infection rates compared to synthetic ePTFE grafts. Drug-eluting grafts, although only 10% of the market, reduce thrombosis by nearly 30% and extend patency to beyond 24 months. Emerging grafts with antimicrobial coatings are expected to reduce infection rates by up to 50%. With more than 3 million dialysis patients globally, even a 10% shift toward advanced grafts represents an additional 300,000 placements annually, creating significant AV Graft Market Opportunities for manufacturers.

CHALLENGE

"High procedural and replacement costs burden patients and systems."

AV grafts cost 20–40% more than fistulas, with additional expenses incurred due to complications. On average, patients with grafts require 1.5 interventions annually, compared to 0.5 for fistula patients. This results in 500,000–600,000 additional procedures globally each year. In countries with limited reimbursement, such as parts of Asia and Africa, this cost limits adoption. For example, in India, less than 15% of dialysis patients currently have AV grafts due to affordability issues. This financial challenge continues to hinder AV Graft Market Growth in developing economies.

AV Graft Market Segmentation

The AV Graft Market segmentation is defined by type and application, with synthetic grafts dominating.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

ePTFE: ePTFE grafts account for 60% of the global market, with more than 400,000 units implanted annually. Their average patency ranges between 12–18 months, and 15–20% are heparin-bonded to improve outcomes.

The ePTFE segment in the global AV Graft market is estimated to reach USD 137.14 million in 2025, holding a 60% share, and projected to grow to USD 336.31 million by 2034 at a CAGR of 10.6%.

Top 5 Major Dominant Countries in the ePTFE Segment

• United States: ePTFE graft market is expected to reach USD 42.5 million by 2025, representing a 31% share, projected to grow to USD 104.4 million by 2034 at a 10.5% CAGR.
• Germany: Market estimated at USD 13.1 million in 2025 with 9.6% share, expected to expand to USD 31.8 million by 2034, recording a CAGR of 10.4%.
• China: Accounts for USD 16.4 million in 2025 at a 12% share, projected to reach USD 40.6 million by 2034, maintaining a CAGR of 10.7%.
• Japan: Valued at USD 9.6 million in 2025 with a 7% share, anticipated to increase to USD 23.8 million by 2034, growing steadily at a 10.5% CAGR.
• India: Estimated at USD 7.5 million in 2025 with a 5.5% share, projected to reach USD 18.8 million by 2034, recording a CAGR of 10.6%.

Biological Materials: Biological grafts make up 25% of demand, with around 160,000 units implanted each year. They are often preferred in patients with higher infection risks and provide patency beyond 24 months.

The biological materials segment is projected at USD 57.14 million in 2025, capturing 25% of the market, and forecasted to reach USD 137.2 million by 2034 at a CAGR of 10.5%.

Top 5 Major Dominant Countries in the Biological Materials Segment

• United States: Market at USD 17.1 million in 2025 with 29.9% share, projected to expand to USD 41.5 million by 2034, achieving a CAGR of 10.4%.
• France: Valued at USD 6.8 million in 2025 with 11.9% share, expected to reach USD 16.5 million by 2034, sustaining a CAGR of 10.6%.
• China: USD 8.5 million in 2025 with a 14.9% share, anticipated to reach USD 20.5 million by 2034, advancing at a CAGR of 10.5%.
• Japan: USD 5.7 million in 2025 at a 10% share, forecasted to expand to USD 13.7 million by 2034, achieving CAGR of 10.6%.
• India: USD 4.2 million in 2025 with 7.3% share, expected to increase to USD 10.1 million by 2034, growing steadily at 10.5% CAGR.

Others: Hybrid and novel materials represent 15% of the market, equating to 100,000 annual placements. These combine synthetic and biological advantages, reducing intervention frequency by up to 40%.

The others segment is estimated at USD 34.28 million in 2025, contributing 15% of the global share, projected to grow to USD 86.37 million by 2034, registering a CAGR of 10.4%.

Top 5 Major Dominant Countries in the Others Segment

• United States: Market estimated at USD 10.6 million in 2025 with 30.9% share, projected to reach USD 26.8 million by 2034, growing at a CAGR of 10.4%.
• United Kingdom: Valued at USD 3.1 million in 2025 with 9% share, anticipated to increase to USD 7.8 million by 2034, expanding at 10.5% CAGR.
• China: USD 4.5 million in 2025 with a 13.1% share, forecasted to reach USD 11.1 million by 2034, with a CAGR of 10.6%.
• Japan: USD 2.7 million in 2025 at an 8% share, expected to rise to USD 6.6 million by 2034, maintaining a CAGR of 10.5%.
• Brazil: USD 1.9 million in 2025 with 5.5% share, projected to reach USD 4.7 million by 2034, achieving CAGR of 10.6%.

BY APPLICATION

Hospitals: Hospitals account for 70% of AV graft placements globally, with over 500,000 annual procedures performed in surgical centers. Hospitals also handle more than 80% of complicated graft revisions.

The hospitals application segment is estimated at USD 159.99 million in 2025, representing 70% of the market share, and projected to reach USD 391.9 million by 2034 at a CAGR of 10.5%.

Top 5 Major Dominant Countries in the Hospitals Application

• United States: Market valued at USD 48 million in 2025 with a 30% share, projected to increase to USD 117.7 million by 2034, achieving a CAGR of 10.5%.
• Germany: USD 11.5 million in 2025 with 7.2% share, anticipated to expand to USD 28.2 million by 2034, advancing at a CAGR of 10.6%.
• China: USD 14.4 million in 2025 with 9% share, expected to reach USD 35.4 million by 2034, sustaining CAGR of 10.5%.
• Japan: USD 8.3 million in 2025 with 5.2% share, forecasted to rise to USD 20.3 million by 2034, growing at a CAGR of 10.6%.
• India: USD 6.7 million in 2025 with 4.2% share, projected to reach USD 16.5 million by 2034, recording a CAGR of 10.5%.

Clinics: Clinics contribute 30% of placements, equivalent to 200,000 procedures annually. Dialysis-focused centers increasingly handle initial graft insertions, particularly in developed markets.

The clinic application segment is valued at USD 68.57 million in 2025, capturing 30% of the market, and projected to reach USD 167.96 million by 2034 at a CAGR of 10.4%.

Top 5 Major Dominant Countries in the Clinic Application

• United States: USD 20.6 million in 2025 with a 30% share, forecasted to expand to USD 50.5 million by 2034, recording a CAGR of 10.5%.
• France: Valued at USD 5.8 million in 2025 with 8.5% share, expected to reach USD 14.2 million by 2034, growing at 10.6% CAGR.
• China: USD 6.9 million in 2025 with a 10% share, projected to reach USD 17 million by 2034, sustaining CAGR of 10.5%.
• Japan: USD 4.1 million in 2025 with 6% share, anticipated to reach USD 10.1 million by 2034, advancing at CAGR of 10.6%.
• India: USD 3.4 million in 2025 with 5% share, forecasted to increase to USD 8.4 million by 2034, growing at 10.5% CAGR.

AV Graft Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America accounts for 35% of the global AV graft market, with the U.S. leading at more than 100,000 procedures annually. Canada performs around 10,000 procedures, and Mexico adds 8,000–9,000. In North America, ePTFE grafts dominate with 70% share, while biologics make up 20%. Hospitals conduct 75% of procedures, and clinics manage the remainder. Complication-related revisions occur in 25–30% of patients annually, creating sustained replacement demand.

The North America AV Graft market is projected at USD 91.4 million in 2025, accounting for 40% of global share, expected to reach USD 223.9 million by 2034 at a CAGR of 10.5%.

North America - Major Dominant Countries in the AV Graft Market

• United States: USD 73.1 million in 2025 with 80% regional share, projected to expand to USD 179 million by 2034, sustaining a CAGR of 10.5%.
• Canada: Valued at USD 9.1 million in 2025 with 10% share, anticipated to increase to USD 22.3 million by 2034, maintaining a CAGR of 10.6%.
• Mexico: USD 6.4 million in 2025 with 7% share, forecasted to reach USD 15.7 million by 2034, advancing at 10.5% CAGR.
• Brazil (linked regionally for trade): USD 2.1 million in 2025 with 2% share, projected to rise to USD 5.1 million by 2034, sustaining CAGR of 10.6%.
• Chile: USD 0.7 million in 2025 with 1% share, expected to grow to USD 1.8 million by 2034, recording CAGR of 10.5%.

Europe

Europe holds 30% of the market, with approximately 80,000–100,000 graft placements each year. Germany leads with 25,000–30,000 procedures, France with 20,000–22,000, and the UK with 18,000–20,000. ePTFE grafts represent 60% of European use, while biological grafts account for 30%. Hospitals are the primary centers for procedures, conducting more than 85% of graft insertions. Revisions and complications add an estimated 20,000 procedures annually.

The Europe AV Graft market is valued at USD 68.6 million in 2025 with a 30% share, projected to reach USD 168 million by 2034, recording a CAGR of 10.4%.

Europe - Major Dominant Countries in the AV Graft Market

• Germany: USD 17.1 million in 2025 with 25% share, forecasted to grow to USD 41.8 million by 2034, achieving CAGR of 10.5%.
• France: Valued at USD 13.7 million in 2025 with 20% share, expected to reach USD 33.5 million by 2034, sustaining a CAGR of 10.5%.
• United Kingdom: USD 10.3 million in 2025 with 15% share, projected to increase to USD 25.1 million by 2034, advancing at 10.6% CAGR.
• Italy: USD 9.6 million in 2025 with 14% share, anticipated to grow to USD 23.4 million by 2034, maintaining CAGR of 10.5%.
• Spain: USD 6.9 million in 2025 with 10% share, expected to rise to USD 16.8 million by 2034, expanding at 10.6% CAGR.

Asia-Pacific

Asia-Pacific represents 25% of the global market, with over 1.8 million dialysis patients driving new demand. China records 40,000–50,000 graft placements annually, while India performs 25,000–30,000, and Japan exceeds 20,000. ePTFE grafts comprise 55% of regional use, biological grafts 30%, and others 15%. Clinics handle more than 40% of procedures in emerging economies due to rapid dialysis center expansion. Annual revision procedures exceed 30,000 due to higher infection rates.

The Asia AV Graft market is projected at USD 57.1 million in 2025 with a 25% share, expected to reach USD 139.9 million by 2034 at a CAGR of 10.5%.

Asia - Major Dominant Countries in the AV Graft Market

• China: USD 19.9 million in 2025 with 35% share, forecasted to reach USD 48.6 million by 2034, sustaining CAGR of 10.6%.
• Japan: USD 11.4 million in 2025 with 20% share, projected to grow to USD 27.9 million by 2034, advancing at 10.5% CAGR.
• India: Valued at USD 9.7 million in 2025 with 17% share, expected to increase to USD 23.7 million by 2034, maintaining CAGR of 10.5%.
• South Korea: USD 6.3 million in 2025 with 11% share, forecasted to reach USD 15.4 million by 2034, expanding at 10.6% CAGR.
• Australia: USD 4.6 million in 2025 with 8% share, projected to rise to USD 11.2 million by 2034, sustaining CAGR of 10.5%.

Middle East & Africa

Middle East & Africa contribute 10% of global demand, with South Africa performing 5,000 procedures, Saudi Arabia 7,000, and the UAE 4,000 annually. Across Africa, fewer than 10,000 AV grafts are placed each year due to affordability. Synthetic grafts dominate at 70%, with biological grafts at 20%. Hospitals perform over 85% of procedures. Complication rates are higher in this region, with up to 40% of grafts requiring revision annually, reflecting gaps in infection control.

The Middle East and Africa AV Graft market is valued at USD 11.4 million in 2025 with 5% global share, expected to reach USD 28 million by 2034 at a CAGR of 10.6%.

Middle East and Africa - Major Dominant Countries in the AV Graft Market

• Saudi Arabia: USD 3.4 million in 2025 with 30% share, projected to expand to USD 8.3 million by 2034, sustaining CAGR of 10.6%.
• United Arab Emirates: USD 2.3 million in 2025 with 20% share, forecasted to rise to USD 5.6 million by 2034, advancing at CAGR of 10.5%.
• South Africa: USD 2 million in 2025 with 18% share, expected to reach USD 4.8 million by 2034, sustaining CAGR of 10.5%.
• Egypt: USD 1.5 million in 2025 with 13% share, projected to increase to USD 3.7 million by 2034, recording CAGR of 10.6%.
• Nigeria: USD 0.9 million in 2025 with 8% share, anticipated to grow to USD 2.2 million by 2034, sustaining CAGR of 10.5%.

List of Top AV Graft Companies

• Artivion
• BIOVIC Sdn Bhd.
• Braun Melsungen AG
• BD
• L. Gore & Associates
• Merit Medical
• Getinge
• LeMaitre

Top Two Companies With Highest Share

• L. Gore & Associates dominates with over 30% of the global AV graft market, producing more than 200,000 grafts annually.
• B. Braun Melsungen AG follows with a 15% share, distributing over 100,000 grafts annually across hospitals worldwide.

Investment Analysis and Opportunities

Investments in the AV Graft Market are increasingly directed toward advanced biomaterials and coated grafts. Developing a heparin-bonded graft production line requires capital expenditure of USD 10–15 million, with manufacturing capacity of 50,000–100,000 units annually. Biological graft production facilities process 20,000–30,000 units per year, requiring specialized sterilization and storage infrastructure. Market opportunities lie in Asia-Pacific, where more than 1.8 million dialysis patients remain underserved, and graft adoption is less than 20%. Increasing investment in dialysis clinics in India and China creates room for an additional 50,000–70,000 graft placements annually. North America continues to attract investors due to the 100,000 procedures performed yearly and the high revision rate of 25–30%.

New Product Development

Product innovation is reshaping the AV Graft Market. Drug-eluting grafts have reduced thrombosis by 30%, while antimicrobial coatings have lowered infection rates by nearly 50%. Hybrid grafts combining ePTFE and biologics extend patency by up to 24 months and reduce interventions by 40%. Biodegradable grafts, though in early stages, are being tested in pilot studies involving 500–1,000 patients. 3D printing technology now enables customized grafts, with early models reducing surgical time by 15–20%. Leading companies have launched more than 20 new graft products over the past three years, with 25% incorporating drug delivery capabilities. These innovations are designed to extend graft lifespans and minimize healthcare costs.

Five Recent Developments

• L. Gore & Associates launched a heparin-bonded ePTFE graft, increasing patency rates by 20%.
• Braun expanded graft production capacity by 25%, reaching 120,000 annual units.
• Merit Medical introduced antimicrobial-coated grafts, reducing infection rates by 40% in clinical trials.
• Getinge invested in biologic graft R&D, testing bovine-derived products in over 2,000 patients.
• LeMaitre acquired a vascular graft startup, expanding its portfolio by 15%.

Report Coverage of AV Graft Market

This AV Graft Market Report covers global supply, demand, product segmentation, and regional performance. It highlights that 3.2 million dialysis patients rely on vascular access, with 600,000 living with AV grafts. ePTFE grafts dominate at 60% of usage, biological grafts represent 25%, and others cover 15%. Regional analysis shows North America at 35% share, Europe at 30%, Asia-Pacific at 25%, and Middle East & Africa at 10%. The report profiles leading companies, with W. L. Gore holding over 30% share and B. Braun at 15%. It details investment needs, clinical complication rates, and product innovation. The AV Graft Industry Report emphasizes AV Graft Market Trends such as drug-eluting and antimicrobial grafts, while also outlining AV Graft Market Opportunities in emerging dialysis regions.

AV Graft Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 357.81 Million in 2026
Market Size Value By	USD 618.5 Million by 2035
Growth Rate	CAGR of 10.47% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : ePTFE Biological Materials Others By Application : Hospitals Clinic
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample